Bottom line
Is LABU a good fund? The bottom line
LABU is an index leveraged & inverse ETF from Direxion.
It charges 0.96% — about $96 a year on every $10,000 invested, cheaper than 80% of leveraged & inverse funds we track.
It returned +78.7% over one year, −39.6% a year over five years, −20.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $494 million in net assets and 163 holdings, its largest position is Dreyfus (15.9%) and the top 10 make up 64.8% of the portfolio.
What stands out
- Low cost: cheaper than 80% of leveraged & inverse peers
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 64.8% of assets
- High turnover (107% a year) can mean more taxable distributions
Updated Nov 19, 2026
What LABU invests in
The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
"The Index is provided by S&P Dow Jones Indices (the Index Provider) and includes domestic companies from the biotechnology industry. The Index is a modified equal-weighted index that is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). GICS classifications are determined primarily based on a companys revenues, however, earnings and market perception are also considered by GICS. The Index consists of constituents of the S&P Total Market Index (S&P TMI) that belong to the GICS biotechnology sub-industry that satisfy the following criteria: (1) have a float-adjusted market capitalization above $300 million with a float-adjusted liquidity ratio (defined by dollar value traded over the previous 12 months divided by the float-adjusted market capitalization as of the Index rebalancing reference date) above 50%…
From the fund's prospectus (filed Mar 3, 2026).
LABU performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| LABU | +78.7% | −39.6% | −20.8% |
| Leveraged & Inverse median | −7.7% | −11.8% | −13.5% |
Source: Fund prospectus, as of Dec 31, 2025
What LABU costs
On a $10,000 investment, LABU's 0.96% expense ratio costs about $96 a year. The prospectus estimates $1,178 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
LABU top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Dreyfus | 15.86% |
| 2 | Goldman Financial | 14.83% |
| 3 | N/a | 9.63% |
| 4 | N/a | 7.30% |
| 5 | Goldman Sachs Liq Es Fd A | 5.35% |
| 6 | N/a | 4.85% |
| 7 | N/a | 3.87% |
| 8 | Apogee Therapeutics Inc APGE | 1.11% |
| 9 | Oruka Therapeutics Inc ORKA | 1.03% |
| 10 | Dianthus Therapeutics Inc DNTH | 0.96% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 64.8% of the fund. See all top 25 holdings and asset mix →